Program
sintilimab
Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.
Drug pageSintilimab: every studyMany companies study it; this page follows only the 40 they lead. All 403 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 295 open or running | phase 3since May 7, 2017 | Oct 8, 2016 | Mar 25, 2030phase 3 · NCT07917468 |
| HUTCHMEDits history only | 31 open or running | phase 3since Aug 16, 2022 | Mar 27, 2019 | Jan 8, 2029phase 3 · NCT06584032 |
| Beijing Aosaikang Pharmaceuticalits history only | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Chipscreen Biosciencesits history only | 11 open or running | phase 3since Jun 28, 2024 | Jun 28, 2024 | May 31, 2028phase 3 · NCT06497985 |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 2since Jul 30, 2026 | Jul 30, 2026 | Sep 30, 2029phase 2 · NCT07761286 |
| Sichuan Luzhou Buchang Biopharmaceuticalits history only | 11 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 1since Jan 29, 2023 | Jan 29, 2023 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 11 open or running | phase 2since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| TaiRxits history only | 11 open or running | phase 2since Mar 31, 2026 | Mar 31, 2026 | Dec 31, 2027phase 2 · NCT07521852 |
| TJ Biopharmaits history only | 11 open or running | phase 2since May 21, 2025 | May 21, 2025 | none ahead |
Also a collaborator on its studies: Fortrea.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Innovent Biologics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 15 earlier studies, Oct 8, 2016 to Feb 18, 2020.
- Jun 9, 2018Named sintilimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, IBI308
- Apr 17, 2020Phase 1 study in Advanced MalignanciesNCT04353830 · 34 enrolled · China
- May 6, 2020Phase 1 study in Advanced Hepatocellular CarcinomaNCT04401813 · 97 enrolled · China
- Jun 9, 2020Phase 1 study in Advanced or Metastatic Solid TumorsNCT04427774 · 8 enrolled · China
- Dec 3, 2020Phase 3 study in Gastric AdenocarcinomaNCT04675983 · 36 enrolled · China
- Sep 1, 2021Phase 1 study in DLBCLNCT05039658 · 50 enrolled · China
- Oct 26, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05116462 · 506 enrolled · China
- Nov 3, 2021Phase 1 study in Solid TumorNCT05119998 · 48 enrolled · China
- Mar 6, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05280626 · 100 planned
- Mar 22, 2022Phase 1 study in Healthy Male SubjectsNCT05337267 · 117 enrolled · China
- Oct 5, 2022Phase 2 study in MelanomaNCT05572463 · United States, Australia, France and more
- Apr 17, 2023Phase 2 study in Non-squamous Non-small-cell Lung CancerNCT05849246 · 4 enrolled · China
- Mar 16, 2026Phase 2 study in CLDN18.2 PositiveNCT07483567 · 90 planned · China
- Jun 4, 2026Phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaNCT07643623 · 720 planned · China
- Oct 19, 2026Phase 3 study in Locally Advanced Rectal CancerNCT07917468 · 500 planned · China
Ahead
- Mar 25, 2030Primary completion: phase 3 study in Locally Advanced Rectal CancerNCT07917468
- Jun 30, 2030Primary completion: phase 2 study in CLDN18.2 PositiveNCT07483567
- Dec 31, 2031Primary completion: phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaNCT07643623
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 29 Innovent Biologics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07917468Locally Advanced Rectal Cancer · China | 3 | Not yet recruiting | Mar 25, 2030 | 500 |
| NCT07643623Resectable Gastric/Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Dec 31, 2031 | 720 |
| NCT07483567CLDN18.2 Positive · China | 2 | Recruiting | Jun 30, 2030 | 90 |
| NCT05849246Non-squamous Non-small-cell Lung Cancer · China | 2 | Terminated | Nov 30, 2023 | 4 |
| NCT05572463Melanoma · United States, Australia, France and more | 2 | Withdrawn | Jun 30, 2027 | 0 |
| NCT05337267Healthy Male Subjects · China | 1 | Completed | May 24, 2023 | 117 |
| NCT05280626Lymphoma, Large B-Cell, Diffuse | 2 | Not yet recruiting | Dec 31, 2025 | 100 |
| NCT05119998Solid Tumor · China | 1 | Completed | Jul 27, 2023 | 48 |
| NCT05116462Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sep 30, 2026 | 506 |
| NCT05039658DLBCL · China | 1 | UNKNOWN | Jul 12, 2022 | 50 |
| NCT04675983Gastric Adenocarcinoma · China | 3 | Terminated | Feb 12, 2023 | 36 |
| NCT04427774Advanced or Metastatic Solid Tumors · China | 1 | Terminated | Feb 8, 2021 | 8 |
| NCT04401813Advanced Hepatocellular Carcinoma · China | 1 | Completed | Jun 21, 2024 | 97 |
| NCT04353830Advanced Malignancies · China | 1 | Completed | May 11, 2022 | 34 |
| NCT04277663Acral Melanoma That Has Been Removed by Surgery · China | 3 | Terminated | Feb 28, 2023 | 136 |
| NCT04258111Colorectal Neoplasms · China | 2 | Terminated | Oct 26, 2020 | 4 |
| NCT04177290Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Feb 28, 2021 | 48 |
| NCT04085185Advanced Malignancies · China | 1 | UNKNOWN | Dec 15, 2023 | 268 |
| NCT04044222Classic Hodgkin's Lymphoma · China | 3 | UNKNOWN | Jul 30, 2023 | 240 |
| NCT03802240Non-Squamous Non-Small Cell Lung Cancer · China | 3 | Completed | Jul 31, 2021 | 492 |
| NCT03745170Stomach Neoplasms · China | 3 | Completed | Jun 20, 2021 | 650 |
| NCT03748134Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Completed | Sep 9, 2021 | 746 |
| NCT03629925Squamous NSCLC · China | 3 | Completed | Mar 25, 2020 | 357 |
| NCT03607539Lung Neoplasms · China | 3 | Completed | Nov 15, 2019 | 397 |
| NCT03568539Advanced/Metastatic Solid Malignancies · United States | 1 | Completed | Nov 9, 2020 | 39 |
| NCT03228836Effect of Drugs · China | 2 | Completed | Feb 28, 2020 | 28 |
| NCT03150875Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Feb 22, 2023 | 290 |
| NCT03116152Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Oct 2, 2019 | 190 |
| NCT02937116Neoplasms · China | 1 | Completed | Sep 30, 2020 | 233 |
How it is read
Names in the registry
- “Sintilimab”, 15 entries
- “IBI308”, 5 entries
- “IBI939+ Sintilimab”, 2 entries
- “IBI110+ Sintilimab”, 2 entries
- “fruquintinib+sintilimab”, 1 entry
Codes read as this program: IBI308.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Hepatocellular, 4 studies
- Stomach Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.